High-dose therapy of berkitt's lymphoma in patients over 40 years of age


Cite item

Full Text

Abstract

Aim. To analyse efficacy and tolerance of high-dose polychemotherapy (PCT) of Berkitt's lymphoma (BL) in patients aged over 40 years. Material and methods. High-dose PCT was given to 6 BL patients aged 41-56 years (median 48.1 years). Results. Complete clinicohematological remissions were achieved in 4 patients. In two of them the treatment was discontinued after three blocks of PCT because of severe infectious complications. According to 4-12 month follow-up, remission continues. Remission was not achieved in two patients: one patient had primary resistance, the other died of sepsis after the second PCT course before remission. The time to remission did not correlate with age. Duration of myelotoxic agranulocytosis varied from 2 to 24 days. Duration of agranulocytosis did not correlate with age. Infections complicated 19 of 20 PCT blocks. Severity of complications caused withdrawal of three patients. Conclusion. BL is biologically heterogenous as it demonstrates different responses to BL-M-04 program. Causes of slow regression of tumor mass in some patients need further investigations. In spite of a great number of infectious complications high-dose therapy has no alternative.

About the authors

S K Kravchenko

ГУ Гематологический научный центр РАМН, Москва

E A Bariakh

ГУ Гематологический научный центр РАМН, Москва

V I Zamiatina

ГУ Гематологический научный центр РАМН, Москва

T N Perestoronina

ГУ Гематологический научный центр РАМН, Москва

O S Fink

ГУ Гематологический научный центр РАМН, Москва

A V Gubkin

ГУ Гематологический научный центр РАМН, Москва

E K Egorova

ГУ Гематологический научный центр РАМН, Москва

E E Zvonkov

ГУ Гематологический научный центр РАМН, Москва

E A Iliushkina

ГУ Гематологический научный центр РАМН, Москва

B B Krasil'nikova

ГУ Гематологический научный центр РАМН, Москва

A K Morozova

ГУ Гематологический научный центр РАМН, Москва

I A Vorob'ev

ГУ Гематологический научный центр РАМН, Москва

I B Kaplanskaia

ГУ Гематологический научный центр РАМН, Москва

G A Kliasova

ГУ Гематологический научный центр РАМН, Москва

T N Obukhova

ГУ Гематологический научный центр РАМН, Москва

A M Kremenetskaia

ГУ Гематологический научный центр РАМН, Москва

A I Vorob'ev

ГУ Гематологический научный центр РАМН, Москва

References

  1. Воробьев А. И. (ред.). Руководство по гематологии. М.: Изд-во "Ньюдиамед"; 2002; т. 2: 101.
  2. Harris N. L., Jaffe Е. S., Diebold J. et al. World Health Organization classification diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999; 17 (12): 3835-3849.
  3. Warnke R., Weiss L., Chan J. et al. Atlas of tumor pathologies. Tumors of the lymph nodes and spleen. Washington: Armed Forces Institute of Pathology; 1999: 221-232.
  4. Blum K. A., Lozansky G., Byrd J. Adult Burkitt's leukemia and lymphoma. Blood 2004; 104 (10): 3009-3020.
  5. Patte C., Auperin A., Michon J. et al. The Societe Francaise d'Oncologie pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 inselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-3379.
  6. Lones M. A., Sanger W. G., Le Beau M. M. et al. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents. J. Pediatr. Hematol. Oncol. 2004; 26 (3): 169-178.
  7. Барях E. А. Диагностика и лечение лимфомы Беркитта: Дис. ... канд. мед. наук. М.: 2007.
  8. Skorokhod О., Kulikova Е. V., Galkina N. М. et al. Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded erythrocytes. Haematologica 2007; 92 (4): 570-571.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies